GLP-1 drugs have become the hottest drug class in a generation, driven by an obesity epidemic affecting 40% of American adults and linked to diabetes, heart disease and a growing list of other conditions. But there’s a catch: up to two-thirds of adults report some level of needle fear. A 2022 PLOS One international survey…
Pharma M&A, China deals and GLP-1s: What to watch in 2026
The pharmaceutical industry heads into 2026 carrying strong M&A momentum, a surging Chinese deal landscape and continued buzz around obesity drugs and new modalities. Deals involving Chinese pharma and biotech firms reached $92.2 billion in potential value through November 2025. That’s nearly double the $51.9 billion recorded in 2024, according to Mark Lansdell, Director, Asset…